Julie A. Margenthaler, MD | Authors

Molecular Profiling Assays in Breast Cancer: Beyond Prime Time and Into Syndication

April 17, 2012

Future randomized studies should focus on determining which patients benefit most from the inclusion of molecular diagnostics in treatment decision making and on the development of treatment algorithms that incorporate patient factors, histologic and biologic findings, and molecular markers.

Margin Status Following Partial Mastectomy: One Size Does Not Fit All!

September 14, 2011

Breast-conserving therapy (BCT), which includes wide local excision of the tumor followed by irradiation, has become a standard treatment option for women with early-stage invasive breast cancer.